APUS
Apimeds Pharmaceuticals US, Inc.Marquee-fund ownership over time
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Renaissance Technologies | Q4 2025 | Q1 2026 | → $11 | -61% |
| Citadel Advisors | Q3 2025 | Q4 2025 | → $32 | +103% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Apimeds Pharmaceuticals US, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Nov 21, 2025 — the most recent Form 4 on file — not from today.
- Form 4/Aamend0002057997-25-000002Nov 21, 2025
- Form 40002040378-25-000004Nov 13, 2025
- Form 40002041300-25-000003Nov 13, 2025
- Form 40002041972-25-000004Nov 13, 2025
- Form 40001573840-25-000003Nov 13, 2025
- Form 40001679971-25-000008Nov 13, 2025
- Form 40001679971-25-000007Oct 24, 2025
- Form 40001573840-25-000002Oct 21, 2025
- Form 40002041972-25-000003Oct 17, 2025
- Form 40002040378-25-000003Oct 17, 2025
- Form 40002040022-25-000002Oct 17, 2025
- Form 40002041300-25-000002Oct 17, 2025
- Form 40001710496-25-000002Oct 17, 2025
- Form 4/Aamend0001474506-25-000109Jun 11, 2025
- Form 40001474506-25-000103May 20, 2025
Fundamentals
XBRL · Apimeds Pharmaceuticals US, Inc.Annual figures sourced directly from Apimeds Pharmaceuticals US, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Apimeds Pharmaceuticals US, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQUARTERLY REPORTMay 26, 2026
- 8-KCURRENT REPORTMay 5, 2026
- 10-KANNUAL REPORTMay 4, 2026
- 8-KCURRENT REPORTMay 4, 2026
- 8-KFORM 8-KApr 22, 2026
- 8-KCURRENT REPORTApr 16, 2026
- 8-K/AAMENDMENT NO. 1 TO FORM 8-KApr 9, 2026
- 8-KCURRENT REPORTMar 26, 2026
- 8-KCURRENT REPORTMar 25, 2026
- 8-KCURRENT REPORTMar 16, 2026
- 8-K/AAMENDMENT NO. 2 TO FORM 8-KFeb 17, 2026
- 8-KCURRENT REPORTJan 2, 2026
- 8-KCURRENT REPORTDec 10, 2025
- 8-K/AAMENDMENT NO. 1 TO FORM 8-KDec 10, 2025
- 8-KCURRENT REPORTDec 2, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Renaissance Technologies | Q4 2025 | Q1 2026 | $28 | $11 | -61% |
| Citadel Advisors | Q3 2025 | Q4 2025 | $16 | $32 | +103% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.